Advertisement

Bringing in the ACE(i): Angiotensin-Converting Enzyme Inhibitors as Antidepressants

      SEE CORRESPONDING ARTICLE ON PAGE 415
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Duman R.S.
        • Sanacora G.
        • Krystal J.H.
        Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments.
        Neuron. 2019; 102: 75-90
        • Boal A.H.
        • Smith D.J.
        • McCallum L.
        • Muir S.
        • Touyz R.M.
        • Dominiczak A.F.
        • et al.
        Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders.
        Hypertension. 2016; 68: 1132-1138
        • Luo H.
        • Wu P.-F.
        • Cao Y.
        • Jin M.
        • Shen T.-T.
        • Wang J.
        • et al.
        Angiotensin-converting enzyme inhibitor rapidly ameliorates depressive-type behaviors via bradykinin-dependent activation of mammalian target of rapamycin complex 1.
        Biol Psychiatry. 2020; 88: 415-425
        • Fuchikami M.
        • Thomas A.
        • Liu R.
        • Wohleb E.S.
        • Land B.B.
        • DiLeone R.J.
        • et al.
        Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions.
        Proc Natl Acad Sci U S A. 2015; 112: 8106-8111
        • Li N.
        • Lee B.
        • Liu R.J.
        • Banasr M.
        • Dwyer J.M.
        • Iwata M.
        • et al.
        mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
        Science. 2010; 329: 959-964
        • Moda-Sava R.N.
        • Murdock M.H.
        • Parekh P.K.
        • Fetcho R.N.
        • Huang B.S.
        • Huynh T.N.
        • et al.
        Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation.
        Science. 2019; 364: 1-11
        • Miller O.H.
        • Moran J.T.
        • Hall B.J.
        Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition.
        Neuropharmacology. 2016; 100: 17-26
        • Lein E.S.
        • Hawrylycz M.J.
        • Ao N.
        • Ayres M.
        • Bensinger A.
        • Bernard A.
        • et al.
        Genome-wide atlas of gene expression in the adult mouse brain.
        Nature. 2007; 445: 168-176
        • Jean M.
        • Gera L.
        • Charest-Morin X.
        • Marceau F.
        • Bachelard H.
        In vivo effects of bradykinin B2 receptor agonists with varying susceptibility to peptidases.
        Front Pharmacol. 2015; 6: 1-15
        • Abdallah C.G.
        • Averill L.A.
        • Gueorguieva R.
        • Goktas S.
        • Purohit P.
        • Ranganathan M.
        • et al.
        Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.
        Neuropsychopharmacology. 2020; 45: 990-997

      Linked Article